Godfrey Elizabeth L, Mahoney Forest, Bansal Varun V, Su David G, Hanna David N, Lopez-Ramirez Felipe, Baron Ekaterina, Turaga Kiran K, Benson Al B, Setia Namrata, Winer Joshua H, Gunderson Craig G, Shah Rupen, Magge Deepa R, Solsky Ian, Eng Cathy, Eng Oliver S, Shergill Ardaman, Shen John Paul, Misdraji Joseph, Foote Michael B, Luo Wenyi
Department of Surgery, Yale School of Medicine, New Haven, Connecticut, USA.
Yale School of Medicine, New Haven, Connecticut, USA.
Cancer. 2025 Jul 1;131(13):e35874. doi: 10.1002/cncr.35874.
Appendiceal tumors comprise a heterogeneous group of tumors that frequently disseminate to the peritoneum. Management of appendiceal tumors is lacking high-quality data given their rarity and heterogeneity. In general, appendiceal tumor treatment is extrapolated in part from colorectal cancer or pooled studies, without definitive evidence of disease-specific benefit. Many practices are controversial and vary widely between institutions. A national consensus update of best management practices for appendiceal malignancies was performed to better standardize care. Herein, the authors present recommendations for the management of appendiceal tumors with peritoneal involvement.
As previously described, modified Delphi consensus was performed to update the previous 2018 Chicago Consensus guideline. Recommendations were supported by using rapid systematic reviews of key issues in surgical and systemic therapy. Key pathology concepts and recommendations were synthesized in collaboration with content experts.
A consensus-based pathway was generated for any type of non-neuroendocrine appendiceal tumor with peritoneal involvement. The first round of Delphi consensus included 138 participants, of whom 133 (96%) participated in the second round, and greater than 90% consensus was achieved for all pathway blocks. Key items included recommending evaluation for cytoreduction to most patients with low-grade peritoneal disease who are surgical candidates and to many patients with high-grade disease, as well as timing of systemic chemotherapy and surveillance protocols. Common pitfalls in pathologic classification and their clinical implications are also presented.
These consensus recommendations provide guidance regarding the management of appendiceal tumors with peritoneal involvement, including a review of current evidence in the management of recurrent and unresectable disease.
阑尾肿瘤是一组异质性肿瘤，常扩散至腹膜。由于阑尾肿瘤罕见且具有异质性，其管理缺乏高质量数据。一般而言，阑尾肿瘤的治疗部分是从结直肠癌研究或汇总研究中推断而来，缺乏疾病特异性获益的明确证据。许多治疗方法存在争议，不同机构之间差异很大。为了更好地规范治疗，对阑尾恶性肿瘤的最佳管理实践进行了全国性共识更新。在此，作者提出了针对伴有腹膜受累的阑尾肿瘤的管理建议。
如前所述，采用改良德尔菲共识法对2018年芝加哥共识指南进行更新。通过对手术和全身治疗关键问题的快速系统评价来支持各项建议。关键病理概念和建议是与内容专家合作综合得出的。
针对任何类型伴有腹膜受累的非神经内分泌性阑尾肿瘤，生成了一个基于共识的治疗路径。第一轮德尔菲共识有138名参与者，其中133名（96%）参与了第二轮，所有路径模块均达成了超过90%的共识。关键项目包括建议对大多数适合手术的低级别腹膜疾病患者以及许多高级别疾病患者进行细胞减灭评估，以及全身化疗的时机和监测方案。还介绍了病理分类中的常见陷阱及其临床意义。
这些共识建议为伴有腹膜受累的阑尾肿瘤的管理提供了指导，包括对复发性和不可切除疾病管理的现有证据的综述。
